PMID- 1682486
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 259
IP  - 2
DP  - 1991 Nov
TI  - Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine 
      release: effect of dopamine uptake inhibitors.
PG  - 820-5
AB  - The effect of dopamine (DA) and serotonin (5-HT) uptake inhibitors on 
      3,4-methylenedioxymethamphetamine (MDMA)-induced increase in DA efflux was 
      studied using in vivo microdialysis. MDMA was infused directly into the 
      anterolateral striatum via the dialysis probe. The local administration of MDMA 
      produced a dose- and time-dependent increase in the extracellular concentration 
      of DA in the striatum. Peripheral administration of the DA uptake blockers, 
      mazindol (5 mg/kg, i.p.) or GBR 12909 (10 mg/kg, i.p.), produced a slight but 
      significant increase in the extracellular concentration of DA. Moreover, 
      pretreatment with either mazindol or GBR 12909 30 min before the infusion of MDMA 
      (10 microM) significantly attenuated the MDMA-induced increase in the 
      extracellular concentration of DA. Pretreatment with fluoxetine (10 mg/kg, i.p.), 
      a 5-HT uptake blocker, 30 min before the infusion of MDMA produced a slight but 
      significant inhibition of MDMA-induced increase in DA concentration. In contrast, 
      pretreatment with the 5-HT2/1C antagonist, ketanserin (3 mg/kg, i.p.), had no 
      significant effect on the increase in DA concentration produced by the local 
      administration of MDMA. These data are suggestive that MDMA increases the 
      concentration of DA in the striatum, in part, via a carrier-mediated mechanism 
      which is largely independent of its effects on 5-HT release.
FAU - Nash, J F
AU  - Nash JF
AD  - Department of Psychiatry, School of Medicine, Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Brodkin, J
AU  - Brodkin J
LA  - eng
GR  - DA06491/DA/NIDA NIH HHS/United States
GR  - MH 41684/MH/NIMH NIH HHS/United States
GR  - NS07118/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Neurotransmitter Uptake Inhibitors)
RN  - 0 (Piperazines)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 90X28IKH43 (vanoxerine)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - C56709M5NH (Mazindol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology
MH  - Animals
MH  - Corpus Striatum/drug effects/metabolism
MH  - Dialysis/methods
MH  - Dopamine/*metabolism
MH  - Extracellular Space/metabolism
MH  - Fluoxetine/pharmacology
MH  - Ketanserin/pharmacology
MH  - Male
MH  - Mazindol/pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Neurotransmitter Uptake Inhibitors/*pharmacology
MH  - Piperazines/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/physiology
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1991 Nov;259(2):820-5.